Compare Alphabet Inc Class A (GOOGL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs State Street SPDR S&P Biotech ETF — how do they compare? Alphabet Inc Class A trades at $356.34 (market cap $4.52T), while State Street SPDR S&P Biotech ETF trades at $152. The key difference: Alphabet Inc Class A pays a 0.24% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| GOOGL | XBI | |
|---|---|---|
Market Cap | $4.52T | — |
Sector | Media | Broad Market / Factor |
52-Week High | $402.62 | $164.28 |
52-Week Low | $182.97 | $85.16 |
Enterprise Value | $4.49T | — |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $354.37, down 1.43% on the day, amid a bullish technical setup with strong analyst support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $5.11 significantly exceeding the $2.64 estimate. Financial health is solid, with 2025 revenue of $402.84 billion and net income of $132.17 billion, reflecting a net margin of 32.8%. Positive news flow highlights AI-driven growth and strategic partnerships.
Outlook remains positive given earnings momentum, AI expansion, and a consensus price target of $431.78 implying 22% upside. Risks include antitrust scrutiny and tech sector volatility. Institutional sentiment is strongly bullish with 85% buy ratings, supporting a favorable risk-reward profile for long-term investors.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
